New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood

New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably
Determines Carbon Monoxide Levels in the Blood
Researchers Highlight the Unique Advantages of Masimo SpCO(R) to Facilitate
Early Diagnosis of Carbon Monoxide Poisoning On-the-Scene

IRVINE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the
inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that a new peer-reviewed clinical study
published in this month's Inhalation Toxicology demonstrates that Masimo
Rainbow SET® Pulse CO-Oximetry (SpCO) provides reliable measurements of carbon
monoxide (CO) in the blood that facilitate fast, accurate diagnosis of CO
poisoning in pre-hospital emergency and rescue environments.(1)

Carbon monoxide - often called the silent killer - is a colorless, odorless,
tasteless, and deadly gas that is extremely difficult to detect. Prior to
Masimo Rainbow SET Pulse CO-Oximetry, an invasive blood draw followed by
laboratory blood gas analysis was the only reliable method for diagnosing CO
poisoning. Without immediate access to complex and costly laboratory blood
analyzers to measure CO in the blood (COHb), emergency first responders were
at a critical disadvantage - unable to confirm the diagnosis of CO poisoning
necessary to initiate appropriate, often lifesaving treatment. Today, the
portable, handheld Masimo Rad-57 Pulse CO-Oximeter provides an accurate and
noninvasive way to detect elevated CO levels in the bloodstream in just
seconds - allowing emergency first responders to quickly and easily diagnose
CO poisoning on-the-scene and initiate prompt, possibly lifesaving treatment.

Dr. Piatkowski and colleagues at the University Hospital Aachen (Germany) used
the Masimo Rad-57 Pulse CO-Oximeter to measure SpCO in 20 patients suspected
of CO poisoning who were admitted to the burn center and in five healthy
volunteers (used as a control group). Comparing SpCO measurements to COHb
measurements obtained hourly via invasive blood samples processed using three
different laboratory analyzers, researchers found that the mean error of the
three different blood gas analyzers was just 1% lower than noninvasive Pulse
CO-Oximetry. The SpCO measurements from Pulse CO-Oximetry resulted in a mean
error of approximately 3.15% over a COHb range of 1% to 38%, while the
invasive COHb measurements from three different blood analyzers resulted in a
mean error of 2.4%. Researchers concluded that Pulse CO-Oximetry "represents a
reliable measurement technique that is easy to handle and could facilitate the
early diagnosis of CO intoxication in pre-hospital rescue conditions."

Masimo Executive Vice President of Medical Affairs, Dr. Michael O'Reilly,
stated, "This study adds to the compelling evidence base showing that Masimo
Pulse CO-Oximetry SpCO provides accurate and reliable measurements that enable
clinicians and first responders to make earlier and better decisions. This
study is also the first to show that the differences in COHb measurement from
different laboratory analyzers are similar to the differences between
laboratory analyzer measurement and noninvasive Pulse CO-Oximetry
measurement."

(1) A. Piatkowski, D. Ulrich, G. Grieb, N. Pallua. "A New Tool for the Early
Diagnosis of Carbon Monoxide Intoxication." Inhalation Toxicology, November
2009; 21(3):1144-1147.

*Editor's Note: The study is available online at:
http://informahealthcare.com/doi/abs/10.3109/08958370902839754

About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care - helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET®, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements
This press release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, in connection with the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on current expectations
about future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our control
and could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various risk
factors, including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results, risks related to our belief
that Masimo Rainbow SET will provide sufficient sensitivity and specificity to
deliver the most accurate and reliable SpCO measurements under all emergency
and rescue conditions, and risks related to our belief that the Rad-57 enables
fast, reliable, accurate diagnosis of carbon monoxide poisoning, as well as
other factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC, whether as a
result of new information, future events or otherwise, except as may be
required under the applicable securities laws.

Media Contact:
Dana Banks,
Masimo Corporation
949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.

SOURCE Masimo

Dana Banks of Masimo Corporation, +1-949-297-7348